Browsing Bildiri Koleksiyonu by Subject "High-Risk Smoldering Multiple Myeloma"
Now showing items 1-1 of 1
-
Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study
(American Society of Hematology, 2022)Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients ...